Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Denova Research

Neither a doctor nor a teaching hospital

Research payments

$2,255,185

298 payments

Through program year 2025, Denova Research is reported as receiving $2,255,185 in research payments, across 298 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $657,058 77
2024 Research $691,238 90
2023 Research $391,898 76
2022 Research $302,767 35
2021 Research $144,793 14
2020 Research $65,315 3
2019 Research $2,117 3

Breakdown

Who paid Research payments · program years 2019–2025
  1. AbbVie, Inc. $1,180,944 117 payments
  2. Sun Pharmaceutical Industries Inc. $301,351 34 payments
  3. Endo Pharmaceuticals Inc. $173,627 32 payments
  4. Eli Lilly and Company $172,258 10 payments
  5. Amgen Inc. $114,216 7 payments
  6. Allergan Inc. $89,626 4 payments
  7. Merz North America, Inc. $58,975 8 payments
  8. Vanda Pharmaceuticals Inc. $56,950 13 payments
  9. Janssen Research & Development, LLC $56,612 13 payments
  10. Dermavant Sciences, Inc. $37,662 54 payments
Studies the money was for Research payments · program years 2019–2025
  1. Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata $251,633 28 payments
  2. A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) $221,178 18 payments
  3. A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) $188,193 21 payments
  4. A Study to Evaluate Sequential Administration of AGN-151586 and OnabotulinumtoxinA (BOTOX) Injections in Adult Participants for Treatment of Glabellar Lines $169,768 12 payments
  5. BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study $166,901 13 payments
  6. A Phase 2B, Open-Label Long-Term Durability Study of CCH Following Treatment of Edematous Fibrosclerotic Panniculopathy (Cellulite) $89,200 17 payments
  7. A Study to Assess Adverse Events of Intramuscular AGN-151586 Injection in Adult Participants With Glabellar Lines $88,125 13 payments
  8. Efficacy and Safety of Ixekizumab Or Ixekizumab Concomitantly Administered With Tirzepatide in Adult Participants With Moderate-To-Severe Plaque Psoriasis and Obesity Or Overweight: A Phase 3B, Randomized, Multicenter, Open-Label Study (Together-Pso) $72,674 3 payments
  9. A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Lebrikizumab in Adult and Adolescent Participants With Moderate-To-Severe Atopic Hand and Foot Dermatitis $69,906 2 payments
  10. An Open-Label Study to Asses Effects of Mitigation Treatments on Bruising of CCH-Aaes Treatment of Buttock Cellulite in Adult Females--MOBI $67,563 6 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record